Jonathan Strosberg, MD
Although novel therapeutic strategies have shown potential in recent clinical trials, somatostatin analogs are still the frontline standard of care for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), said Jonathan R. Strosberg, MD.
“They are basically frontline drugs, and they are [used in that setting] by virtue of their proven and very significant delay in time to progression, as well as their exceptional tolerability,” said Strosberg. “[Somatostatin analogs] are extremely low-risk drugs compared with pretty much any other drug we administer in the oncology space.”
... to read the full story